Spots Global Cancer Trial Database for datopotamab deruxtecan
Every month we try and update this database with for datopotamab deruxtecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | NCT06176261 | Breast Cancer Breast Cancer F... Metastatic Trip... ER Positive Bre... HER2-negative B... HER2 Negative B... ER-negative Bre... | Datopotamab Der... | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | NCT05687266 | NSCLC | Datopotamab der... Durvalumab Carboplatin Pembrolizumab Cisplatin Pemetrexed Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases | NCT05866432 | Breast Cancer S... | Datopotamab der... | 18 Years - 100 Years | Medical University of Vienna | |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | NCT06350097 | Non-small Cell ... | Osimertinib Datopotamab Der... | 18 Years - | AstraZeneca | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer | NCT04612751 | Advanced or Met... | Datopotamab der... Durvalumab Carboplatin AZD2936 MEDI5752 AZD7789 | 18 Years - | AstraZeneca | |
| A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | NCT05629585 | Breast Cancer | Dato-DXd Durvalumab Capecitabine Pembrolizumab | 18 Years - 130 Years | AstraZeneca | |
| Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients | NCT06279728 | Advanced Non-Sm... Metastatic Non ... | Datopotamab der... | 18 Years - | Daiichi Sankyo | |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | NCT06350097 | Non-small Cell ... | Osimertinib Datopotamab Der... | 18 Years - | AstraZeneca | |
| Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | NCT04526691 | Advanced or Met... | Datopotamab der... KEYTRUDA® Carboplatin Cisplatin | 18 Years - | Daiichi Sankyo | |
| Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | NCT04484142 | Non-small Cell ... | DS-1062a | 18 Years - | Daiichi Sankyo | |
| Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | NCT04484142 | Non-small Cell ... | DS-1062a | 18 Years - | Daiichi Sankyo | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer | NCT04612751 | Advanced or Met... | Datopotamab der... Durvalumab Carboplatin AZD2936 MEDI5752 AZD7789 | 18 Years - | AstraZeneca | |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
